Lupin and Zentiva Sign Pact to Commercialise Certolizumab

10 Jul 2025 CW Team

This strategic alliance aims to accelerate the availability of high-quality, cost-effective biosimilar Certolizumab Pegol to patients worldwide.

Lupin will be responsible for the development, manufacturing and supply of the product within the agreed territories. Zentiva will oversee commercialization activities outside USA and Canada, predominantly in Europe and CIS markets, where it will leverage its extensive European commercial infrastructure and regulatory expertise. Lupin will undertake commercialization in the remaining regions, including USA and Canada.

Both parties will invest in the development of the new biosimilar. Lupin will receive an initial payment of $10 million upon execution of the agreement and total development and regulatory milestone payments up to $50 million. The profits from the defined markets will be shared between the two companies.

Certolizumab Pegol is a recombinant, humanized antibody Fab' fragment, with specificity for human tumor necrosis factor alpha (TNFα), conjugated to an approximately 40kDa polyethylene glycol. It is indicated for the treatment of patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis, moderate-to-severe plaque psoriasis and Crohn’s disease.

“Our global development and commercialization partnership with Zentiva, with its pan- European focus, enables Lupin to commercialize this unique biosimilar in its core markets and through Zentiva in Europe,” said Fabrice Egros, President of Corporate Development, Lupin. “This partnership underscores our dedication to improving the quality of life for individuals living with chronic conditions and ensuring accessibility and affordability of transformative therapies worldwide."

Global Pharma major Lupin (Lupin) and Zentiva Group (Zentiva), a pan-European pharmaceutical company, have entered into a license and supply agreement for commercialisation of Lupin’s biosimilar Certolizumab Pegol, across multiple markets globally.This strategic alliance aims to accelerate the availability of high-quality, cost-effective biosimilar Certolizumab Pegol to patients worldwide.Lupin will be responsible for the development, manufacturing and supply of the product within the agreed territories. Zentiva will oversee commercialization activities outside USA and Canada, predominantly in Europe and CIS markets, where it will leverage its extensive European commercial infrastructure and regulatory expertise. Lupin will undertake commercialization in the remaining regions, including USA and Canada.Both parties will invest in the development of the new biosimilar. Lupin will receive an initial payment of $10 million upon execution of the agreement and total development and regulatory milestone payments up to $50 million. The profits from the defined markets will be shared between the two companies.Certolizumab Pegol is a recombinant, humanized antibody Fab' fragment, with specificity for human tumor necrosis factor alpha (TNFα), conjugated to an approximately 40kDa polyethylene glycol. It is indicated for the treatment of patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis, moderate-to-severe plaque psoriasis and Crohn’s disease.“Our global development and commercialization partnership with Zentiva, with its pan- European focus, enables Lupin to commercialize this unique biosimilar in its core markets and through Zentiva in Europe,” said Fabrice Egros, President of Corporate Development, Lupin. “This partnership underscores our dedication to improving the quality of life for individuals living with chronic conditions and ensuring accessibility and affordability of transformative therapies worldwide.

Real Estate

30 Jul 2026

AI: The New Recruit

From getting ideas to evaluating designs, presenting concepts to clients and tracking projects, artificial intelligence (AI) is helping architects work better and faster.“AI allows architects to spend more time doing what only they can do: think critically, synthesise complexity and design with intent,” says Dikshu C Kukreja, Managing Principal, CP Kukreja Architects. “Every minute reclaimed from repetitive processes can be invested in creativity, contextual understanding, interdisciplinary collaboration and innovation – the qualities that define meaningful architecture.”To read the ..

Real Estate

30 Jul 2026

Redevelopment 2.0

In 2017, Mumbai identified 160,000 ageing buildings due for structural audit. Close to half of these were in the Western Suburbs. Redeveloping the oldest and structurally weakest of these would help unlock new housing, much needed given the city’s growing population density and constant developed area of 437.7 sq km. At 30,600 people per sq km in 2024, Mumbai’s density was almost thrice that of Gurugram, and 60 per cent higher than Bengaluru’s.Essentially, Mumbai’s realty market has demand. It has capital. It has realty development potential.Fast forward to 2026. Mumbai has 1,094 regis..

Technology

30 Jul 2026

Cost intelligence will become a strategic contributor to project success

As India's construction industry accelerates its digital transformation, integrated platforms, AI and connected data are becoming essential to improving cost certainty, project efficiency and sustainability. Ravi Kumar, Sales Director – India, RIB Software India, shares how digital workflows are reshaping project planning, commercial management and decision-making across the construction value chain.India's construction sector is embracing digital technologies at an unprecedented pace. From your perspective, what are the biggest shifts driving this transformation and how is RIB Software enab..